Literature DB >> 19073515

BRCA1: a new genomic marker for non-small-cell lung cancer.

Noemí Reguart1, Andrés Felipe Cardona, Esther Carrasco, Patricia Gomez, Miquel Taron, Rafael Rosell.   

Abstract

We are all aware of the recent rapid changes in cancer management mostly achieved with emerging new data regarding tumor biology. Currently, research in oncology is mainly focused on identifying the unique molecular characteristics of neoplasms and developing new targeted drugs to treat them. Although some tumors have specific genetic alterations that set off a cause-and-effect process after targeted treatment, those who work in the lung cancer field recognize that this is a more complex disease in which various genetic disorders carry its distinctive aggressiveness. At this time, the efforts of the scientific community are directed toward the identification of predictive markers to customize treatment based on specific genomic or protein expression profiles of individual tumors. This report provides a review on the breast cancer susceptibility gene 1, a promising gene determinant of response to different types of chemotherapy and its potential applications as a new molecular marker in lung cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19073515     DOI: 10.3816/CLC.2008.n.048

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  16 in total

1.  PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.

Authors:  Haiying Cheng; Zhenfeng Zhang; Alain Borczuk; Charles A Powell; Adayabalam S Balajee; Howard B Lieberman; Balazs Halmos
Journal:  Carcinogenesis       Date:  2012-12-28       Impact factor: 4.944

2.  ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.

Authors:  Chunxia Su; Songwen Zhou; Ling Zhang; Shengxiang Ren; Jianfang Xu; Jie Zhang; Meijun Lv; Jie Zhang; Caicun Zhou
Journal:  Med Oncol       Date:  2010-05-14       Impact factor: 3.064

3.  KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer.

Authors:  Vienna Ludovini; Biagio Ricciuti; Francesca R Tofanetti; Clelia Mencaroni; Diana Giannarelli; Angelo Sidoni; Maria S Reda; Annamaria Siggillino; Sara Baglivo; Lucio Crinò; Guido Bellezza; Rita Chiari; Giulio Metro
Journal:  Mol Clin Oncol       Date:  2018-10-01

Review 4.  Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?

Authors:  Bartomeu Massuti; Jose Miguel Sanchez; Florentino Hernando-Trancho; Niki Karachaliou; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2013-06

Review 5.  Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?

Authors:  J Thomas De Ligio; Aneliya Velkova; Diego A R Zorio; Alvaro N A Monteiro
Journal:  Anticancer Agents Med Chem       Date:  2009-06       Impact factor: 2.505

6.  BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.

Authors:  M Sung; P Giannakakou
Journal:  Oncogene       Date:  2013-03-25       Impact factor: 9.867

7.  BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer.

Authors:  Katherine V Clark-Knowles; Anna M O'Brien; Johanne I Weberpals
Journal:  J Oncol       Date:  2010-02-22       Impact factor: 4.375

8.  Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1.

Authors:  Sheng-Xiang Ren; Ai-Wu Li; Song-Wen Zhou; Ling Zhang; Yong-Sheng Wang; Bing Li; Xiao-Xia Chen; Jie Zhang; Jian-Fang Xu; Cai-Cun Zhou
Journal:  Chin J Cancer Res       Date:  2012-09       Impact factor: 5.087

9.  ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.

Authors:  M Tiseo; P Bordi; B Bortesi; L Boni; C Boni; E Baldini; F Grossi; F Recchia; F Zanelli; G Fontanini; N Naldi; N Campanini; C Azzoni; C Bordi; A Ardizzoni
Journal:  Br J Cancer       Date:  2013-04-02       Impact factor: 7.640

Review 10.  Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC.

Authors:  Alona Zer; Natasha Leighl
Journal:  Front Oncol       Date:  2014-11-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.